pentoxifylline has been researched along with Myocardial Ischemia in 12 studies
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously shown that pentoxifylline (PTX) protects from vascular complications associated with insulin resistance (IR)." | 7.80 | Pentoxifylline alleviates cardiac ischemia and dysfunction following experimental angina in insulin resistance. ( Azhar, A; El-Bassossy, HM, 2014) |
| "Cilostazol (Pletal), a quinolinone derivative with a cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitory activity, was recently approved by the Food and Drug Administration for treatment of symptoms of intermittent claudication (IC)." | 7.70 | Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. ( Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M, 2000) |
| "We have previously shown that pentoxifylline (PTX) protects from vascular complications associated with insulin resistance (IR)." | 3.80 | Pentoxifylline alleviates cardiac ischemia and dysfunction following experimental angina in insulin resistance. ( Azhar, A; El-Bassossy, HM, 2014) |
| "Cilostazol (Pletal), a quinolinone derivative with a cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitory activity, was recently approved by the Food and Drug Administration for treatment of symptoms of intermittent claudication (IC)." | 3.70 | Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. ( Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M, 2000) |
| "Pentoxifylline treatment resulted in an improvement in functional class (P<0." | 2.71 | Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. ( Badenhorst, D; Candy, G; Essop, R; Kone, VN; Norton, G; Peters, F; Sliwa, K; Woodiwiss, A; Zambakides, C, 2004) |
| "Metformin has unique, intrinsic actions specifically at the level of terminal arterioles, which are completely independent of its antidiabetic effect." | 2.48 | Microvascular diseases: is a new era coming? ( Rapin, JR; Wiernsperger, N, 2012) |
| " A combination of obsidan and trental, 300-400 mg/day, eliminated adverse effects in the microcirculatory bed in the absence of an excessive drop in blood pressure." | 1.29 | [Adverse effects in the microcirculatory bed during obsidan treatment of patients with ischemic heart disease and possibilities of their correction by trental]. ( Kazlovskiĭ, VI, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Matboli, M | 1 |
| Habib, EK | 1 |
| Hussein Mohamed, R | 1 |
| Mahran, NA | 1 |
| Seleem, HS | 1 |
| Nosseir, N | 1 |
| Hasanin, AH | 1 |
| Azhar, A | 1 |
| El-Bassossy, HM | 1 |
| Aslanabadi, N | 1 |
| Shirzadi, HR | 1 |
| Asghari-Soufi, H | 1 |
| Dousti, S | 1 |
| Ghaffari, S | 1 |
| Sohrabi, B | 1 |
| Mashayekhi, SO | 1 |
| Hamishehkar, H | 1 |
| Entezari-Maleki, T | 1 |
| Wiernsperger, N | 1 |
| Rapin, JR | 1 |
| Sliwa, K | 1 |
| Woodiwiss, A | 1 |
| Kone, VN | 1 |
| Candy, G | 1 |
| Badenhorst, D | 1 |
| Norton, G | 1 |
| Zambakides, C | 1 |
| Peters, F | 1 |
| Essop, R | 1 |
| Kang, YM | 1 |
| Zhang, ZH | 1 |
| Xue, B | 1 |
| Weiss, RM | 1 |
| Felder, RB | 1 |
| Eninia, GI | 1 |
| Purinia, IV | 1 |
| Timofeeva, TN | 1 |
| Kazlovskiĭ, VI | 1 |
| Pridjian, AK | 1 |
| Bove, EL | 1 |
| Bolling, SF | 2 |
| Childs, KF | 2 |
| Brosamer, KM | 1 |
| Lupinetti, FM | 1 |
| Olszanski, DA | 1 |
| Ning, XH | 1 |
| Liu, Y | 1 |
| Fong, M | 1 |
| Cone, J | 1 |
| Wang, S | 1 |
| Yoshitake, M | 1 |
| Kambayashi, J | 1 |
| Regensteiner, JG | 1 |
| Hiatt, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pentoxifylline and Myocardial Ischemia
| Article | Year |
|---|---|
Microvascular diseases: is a new era coming?
Topics: Diabetic Angiopathies; Hemorheology; Humans; Metformin; Microcirculation; Microvessels; Myocardial I | 2012 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
2 trials available for pentoxifylline and Myocardial Ischemia
| Article | Year |
|---|---|
A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention.
Topics: Aged; Creatine Kinase, MB Form; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Myo | 2015 |
Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study.
Topics: Adjuvants, Immunologic; Blood Pressure; C-Reactive Protein; Double-Blind Method; Exercise Test; fas | 2004 |
8 other studies available for pentoxifylline and Myocardial Ischemia
| Article | Year |
|---|---|
Pentoxifylline alleviated cardiac injury via modulating the cardiac expression of lncRNA-00654-miR-133a-SOX5 mRNA in the rat model of ischemia-reperfusion.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Male; | 2020 |
Pentoxifylline alleviates cardiac ischemia and dysfunction following experimental angina in insulin resistance.
Topics: Adiponectin; Administration, Oral; Angina Pectoris; Animals; Diet; Disease Models, Animal; Electroca | 2014 |
Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure.
Topics: Action Potentials; Adrenocorticotropic Hormone; Angiotensin II; Animals; Anti-Inflammatory Agents; C | 2008 |
[The effect of kavinton, trental, sermion and kurantil on the blood flow rate in individual segments of the cerebral arteries].
Topics: Blood Flow Velocity; Cerebral Arteries; Chronic Disease; Dipyridamole; Drug Evaluation; Female; Huma | 1994 |
[Adverse effects in the microcirculatory bed during obsidan treatment of patients with ischemic heart disease and possibilities of their correction by trental].
Topics: Adult; Arterioles; Drug Therapy, Combination; Female; Forearm; Humans; Male; Microcirculation; Middl | 1993 |
Developmental differences in myocardial protection in response to 5'-nucleotidase inhibition.
Topics: 5'-Nucleotidase; Aging; Animals; Animals, Newborn; Bicarbonates; Calcium Chloride; Cardiac Output; C | 1994 |
Precursor trapping: a "neonatal" mechanism of myocardial protection.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Animals; Cardiac Surgical Procedures; Heart; In Vitro Techn | 1993 |
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Topics: Adenosine; Animals; Blood Pressure; Cilostazol; Dose-Response Relationship, Drug; Heart Rate; Humans | 2000 |